Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

General Recommendations

For Pruritus, the underlying cause of the itch (ie Acneiform rash, Xerosis or eczema) should be treated. In addition, symptomatic treatment such as menthol cream or antihistamines may be used.1

Treatment

In addition to treating the underlying condition, add the following agents for:

  • Grade 1: topical moisturising/cooling cream containing menthol.
  • Grade 2: oral antihistamines.
  • Grade 3: sedative antihistamines.

Products

  • Menthol 0.5% in cetomacrogol cream.
  • Antihistamines (eg loratadine, cetirizine).
  • Sedative antihistamines (eg hydroxyzine).

EGFRI Treatment

Continue with the selected EGFRI-treatment regimen if adverse events are graded 1 or 2; withhold EGFRI treatment in cases of grade 3 toxicity; continue with the selected EGFRI-treatment regimen only if toxicity mitigates to grade ≤2. Continue with/withold the selected EGFRI-treatment regimen, as recommended in the current and relevant SmPC and according to the patient’s condition. 2,3,4,5,6

References

1Segaert S et al. Eur J Cancer 2009; 45(Suppl 1): 295-308.
2European Medicine Agency.  Tarceva® (erlotinib) Summary of Product Characteristics 2009.
3European Medicine Agency.  Iressa® (gefitinib) Summary of Product Characteristics 2009.
4European Medicine Agency.  Erbitux® (cetuximab) Summary of Product Characteristics 2009.
5European Medicine Agency.  Vectibix® (panitumumab) Summary of Product Characteristics 2009.
6Tyverb® (lapatinib) Summary of Product Characteristics 2010.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings